The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY) (NCT01610934) | Clinical Trial Compass
CompletedPhase 2/3
The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)
Denmark15 participantsStarted 2012-08
Plain-language summary
The purpose of this study is to evaluate the treatment potential of GLP-1-analogues in patients with Maturity Onset Diabetes of the Young (MODY) compared to common treatment.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Caucasian above 18 years of age
* Well characterised MODY3
* Body mass index (BMI) \> 19 kg/m2
* Normal haemoglobin (males \> 8.2 mM, females \> 7.2 mM)
* Normal blood pressure (\< 160/100 mmHg)
* Informed consent
* Capability to perform a light cycling test (heart rate 100-120 beats per minute during 30 minutes)
* Females: use of anticonception (IUC or hormonal)
Exclusion Criteria:
* Heart failure: New York Heart Association class III-IV
* Uraemia, end-stage renal disease, or any other cause of impaired renal function with s-creatinine \> 130 µM and/or albuminuria
* Liver disease (alanine amino transferase (ALAT) and/or aspartate amino transferase (ASAT) \> 2 × upper normal serum levels)
* Anaemia
* Acute or chronic pancreatitis
* Stroma or thyroid cancer
* Pregnancy or breast feeding
* Inability to complete the study
* Treatment naïve patients with HbA1c \< 7.0 %
* Treatment with medicine that can not be paused for 12 hours
* Known allergic reaction to study medication
* Intention to become pregnant
* Unwillingness to complete the protocol